Financial Analysis: Digiliti Money Group (DGLT) vs. CareDx (CDNA)
Digiliti Money Group (OTCMKTS: DGLT) and CareDx (NASDAQ:CDNA) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
This table compares Digiliti Money Group and CareDx’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Digiliti Money Group||-147.73%||N/A||-199.21%|
11.3% of Digiliti Money Group shares are owned by institutional investors. Comparatively, 23.2% of CareDx shares are owned by institutional investors. 50.9% of Digiliti Money Group shares are owned by company insiders. Comparatively, 5.4% of CareDx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This is a breakdown of current ratings for Digiliti Money Group and CareDx, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Digiliti Money Group||0||0||1||0||3.00|
Digiliti Money Group currently has a consensus target price of $6.00, indicating a potential upside of 2,900.00%. CareDx has a consensus target price of $8.88, indicating a potential upside of 29.18%. Given Digiliti Money Group’s higher probable upside, analysts plainly believe Digiliti Money Group is more favorable than CareDx.
Volatility and Risk
Digiliti Money Group has a beta of -1.96, meaning that its share price is 296% less volatile than the S&P 500. Comparatively, CareDx has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Valuation and Earnings
This table compares Digiliti Money Group and CareDx’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Digiliti Money Group||$7.97 million||0.25||-$15.16 million||($6.05)||-0.03|
|CareDx||$40.63 million||4.83||-$39.46 million||($1.81)||-3.80|
Digiliti Money Group has higher earnings, but lower revenue than CareDx. CareDx is trading at a lower price-to-earnings ratio than Digiliti Money Group, indicating that it is currently the more affordable of the two stocks.
CareDx beats Digiliti Money Group on 8 of the 12 factors compared between the two stocks.
Digiliti Money Group Company Profile
Digiliti Money Group, Inc., formerly Digiliti Money, Inc., is a technology solutions and services provider to the financial services industry. The Company’s solutions and services enable its clients, such as banks, credit unions and alternative financial services providers (AFS) to offer their customers remote deposit capture (RDC) and prepaid mobile money technologies and related services. It offers RDC products for businesses and consumers; mobile money management products for consumers, and training and support services for its financial services industry customers. The RDC products are offered to banks and credit unions in the United States, Canada and Latin America. Its mobile money management products are offered to traditional financial institutions (FIs), as well as AFS in the United States, Canada and Latin America. These FIs and AFS providers include banks, credit unions, prepaid card issuers, check cashers and payday lenders.
CareDx Company Profile
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Receive News & Ratings for Digiliti Money Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digiliti Money Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.